文献速递重症综合管理与镇静镇痛

可乐定递减对成人重症患者右美托咪定使用及戒断的影响——一项先导研究

Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study.
PubMed 文献 · Crit Care Explor · 2020-11-03
一句话结论ICU长期右美托咪定输注后,可乐定递减方案未减少戒断症状,但缩短右美托咪定撤药时间并节省费用

这项单中心前瞻性双队列观察研究纳入连续右美托咪定输注至少3天的成人ICU患者,比较可乐定递减(15例)与单纯右美托咪定撤药(27例)的戒断症状发生率。主要终点(停药24小时内单次评估出现至少2项戒断症状)两组无显著差异(73% vs 59%,p=0.51)。可乐定组撤药启动后右美托咪定使用时间更短(19 vs 42小时,p=0.02),人均节省约1553.47美元,未观察到不良反应。提示可乐定可作为长期右美托咪定过渡撤药的安全、有效、实用选择,但未减少戒断症状。

要点

  • 主要终点无差异:停药24小时内单次评估≥2项戒断症状,可乐定组73% vs 单纯撤药组59%(p=0.51)。
  • 可乐定组撤药启动后右美托咪定使用时间更短:19 vs 42小时(p=0.02)。
  • 人均节省费用约1553.47美元,未观察到不良反应。
  • 研究为单中心前瞻性双队列观察,样本量小(42例),可乐定使用由临床医生决定,非随机。
  • 适用人群为连续右美托咪定输注至少3天的成人ICU患者,撤药方式需个体化选择。

适用人群与场景

  • 成人ICU患者,连续右美托咪定输注至少3天,拟撤药者。
  • 场景:三级医院内科-外科ICU、心胸外科ICU和神经外科ICU。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 戒断症状评估:停药24小时内单次评估出现至少2项右美托咪定戒断症状。
  • 长期输注定义:连续右美托咪定输注至少3天。

处置流程与药物剂量

  • 第一步:对连续右美托咪定输注至少3天的成人ICU患者启动撤药。
  • 第二步:由临床医生决定单纯逐渐减停右美托咪定,或加用可乐定递减方案过渡。
  • 第三步:可乐定递减具体剂量、途径、频次及疗程原文未提及。
  • 第四步:撤药期间评估戒断症状,原文未给出具体评估工具或处理阈值。

红旗征与不能漏的情况

  • 右美托咪定骤停后可能出现交感神经戒断症状,原文提及长期输注后突然停药有戒断症状报道,但未列出具体红旗征或处理措施。

研究设计与关键结果

  • 样本量与中心数:42例患者,1个中心;可乐定组15例,单纯撤药组27例。
  • 人群:连续右美托咪定输注至少3天的成人ICU患者。
  • 干预与对照:可乐定递减(由临床医生决定)vs 单纯右美托咪定撤药。
  • 主要终点:停药24小时内单次评估≥2项戒断症状发生率,可乐定组73% vs 单纯撤药组59%,p=0.51,无显著差异。
  • 关键次要终点:撤药启动后右美托咪定使用时间,可乐定组19小时 vs 单纯撤药组42小时,p=0.02。
  • 费用:接受可乐定者人均节省约1553.47美元。
  • 不良事件:未观察到不良反应。

证据类型、等级与局限

  • 证据类型:单中心前瞻性双队列观察研究(先导研究)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:单中心、样本量小(42例)、非随机、可乐定使用由临床医生决定,可能存在选择偏倚;主要终点为单次评估,可能低估戒断症状。

对床旁实践的改变

  • 对连续右美托咪定输注至少3天的成人ICU患者,可乐定递减可作为过渡撤药的选择之一,可缩短右美托咪定撤药时间并节省费用。
  • 可乐定递减未减少戒断症状发生率,不能以预防戒断症状为主要目的常规使用。
  • 适用人群为成人ICU患者,不适用于原文未提及的人群(如儿童、非ICU患者)。
  • 常见陷阱:本研究非随机、样本小,可乐定剂量方案未明确,不能将研究结果等同于标准化推荐。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Prolonged use of dexmedetomidine has become increasingly common due to its favorable sedative and anxiolytic properties. Hypersympathetic withdrawal symptoms have been reported with abrupt discontinuation of prolonged dexmedetomidine infusions. Clonidine has been used to transition patients off dexmedetomidine infusions for ICU sedation. The objective of this study was to compare the occurrence of dexmedetomidine withdrawal symptoms in ICU patients transitioning to a clonidine taper versus those weaned off dexmedetomidine alone after prolonged dexmedetomidine infusion.

DESIGN: This was a single-center, prospective, double cohort observational study conducted from November 2017 to December 2018.

SETTING: Medical-surgical, cardiothoracic, and neurosurgical ICUs in a tertiary care hospital.

PATIENTS: We included adult ICU patients being weaned off dexmedetomidine after receiving continuous infusions for at least 3 days.

INTERVENTIONS: Patients were either weaned off dexmedetomidine alone or with a clonidine taper at the discretion of the providers.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was the incidence of at least two dexmedetomidine withdrawal symptoms during a single assessment within 24 hours of dexmedetomidine discontinuation. Time on dexmedetomidine after wean initiation and difference in medication cost were also evaluated. Forty-two patients were included in this study: 15 received clonidine (Group C) and 27 weaned off dexmedetomidine alone (Group D). There was no significant difference in the incidence of two or more withdrawal symptoms between groups (73% in Group C vs 59% in Group D; p = 0.51). Patients in Group C spent less time on dexmedetomidine after wean initiation compared with patients in Group D (19 vs 42 hr; p = 0.02). An average cost savings of $1,553.47 per patient who received clonidine was observed. No adverse effects were noted.

CONCLUSIONS: Our study demonstrated that patients receiving clonidine were able to wean off dexmedetomidine more rapidly, with a considerable cost savings and no difference in dexmedetomidine withdrawal symptoms, compared with patients weaned off dexmedetomidine alone. Clonidine may be a safe, effective, and practical option to transition patients off prolonged dexmedetomidine infusions.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Bhatt K, Thompson Quan A, Baumgartner L, et al. Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study. Crit Care Explor. 2020. PMID: 33163969. doi:10.1097/CCE.0000000000000245

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。